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INTRODUCTION 
 
Veterinary drugs in general are used for both therapeutic and prophylactic purposes. A third 
application is the use of certain compounds or mixtures of compounds with a view to better 
breeding efficiency. To these belong, among others, the steroids and other substances that have 
similar pharmacological activity and are used to improve the efficiency of protein conversion. 
The better this conversion, the faster the animal grows and the earlier it can be slaughtered. 
These are obvious economic reasons that do not take into account possible harmful effects for 
the consumer of the products derived from the carcass of the slaughtered animal. 
Another group of compounds are the thyrostats, which are sometimes called antihormones 
because they inhibit the activity of the thyroid gland. 
A new class of compounds found its way into animal breeding about two decades ago. The beta-
agonists, sometimes referred to as repartitioners, are licensed only for respiratory diseases in 
cattle and horses. They are being used, however, because they increase the ratio of lean tissue to 
fat.  
Finally, the corticosteroids, of which dexamethasone is probably the most frequently used 
representative, are also being used, apparently with varying success. There is still no unanimity 
as to their mode of action. 
An important feature of thyrostats, beta -agonists, and corticosteroids is that hey are in general 
orally active. This means that they can be given via the fodder or drinking water,leaving no 
trace of percutaneous administration, which is one of the annoying indications when orally 
inactive steroids are injected. 
The European Union (EU) prohibits by Council Directive 96/22/EC the use in stockfarming of 
certain substances having a hormonal or thyrostatic action and of beta-agonists (1). In particular, 
the member states must prohibit. 
(a) the administering to a farm or aquaculture animal, by any means whatsoever, of substances 
having a thyrostatic, oestrogenic, androgenic, or gestagenic action and of beta-agonists ;  
(b) the holding, except under official control, of animals referred to in (a) on a farm, the placing 
on the market or slaughter for human consumption of farm animals that contain the 
substances has been established, unless proof can be given that the animals in question have 
been treated for the exceptional cases mentioned later ; 
(c) the placing on the market for human consumption of aquaculture animals to which 
substances referred to in (a) have been administered and of processed products derived from 
such animals ; 
(d) the placing on the market of meat of the animals referred to in (b) ; 
(e) the processing of meat referred to in (d). 
For therapeutic purposes and under the control of a responsible veterinarian, the administration 
to farm animals of 17ß-estradiol, testosterone, and progesterone and derivatives that readily 
yield the parent compound on hydrolysis after absorption at the site of application may be 
authorized veterinary medicinal products containing (i) allyl trenbolone, administered orally, or 
beta-agonists to equidae and pets, provided they are used in accordance with the manufacturer’s 
instructions, (ii) beta-agonists, in the form of an injection to induce tocolysis in cows when 
calving may be authorized . Again, these veterinary medicinal products must be administered by 
a veterinarian under his direct responsibility. 
Certain zootechnical treatments constitute the second exception to the general prohibition of 
medicinal products having an estrogenic, androgenic, or gestagenic action. In particular, EU 
member states may allow the synchronization of oestrus and the preparation of donors and 
recipients for the implantation of embryos. With regard to aquaculture animals, young fish may 
be treated for the first three months, for the purpose of sex inversion, with veterinary medicinal 
products that have an androgenic action. 
Till August 30, 2002 the organization of the monitoring was maid down by Council Directive 
96/23/EC on measures to monitor certain substances and residues thereof in live animals and 
animal products (2). 
The list of substances and groups of residues to be monitored is show in Table 1. 
 
Table 1 – List of substances and residues listed in Annex I of the Council Directive 96/23/EC 
 
GROUP A – Substances having anabolic effect and unauthorized substances 
 
(1) Stilbenes, stilbene derivatives, and their salts and esters 
(2) Anti thyroid agents 
(3) Steroids 
(4) Resorcylic acid lactones including zeranol 
(5) Beta-agonists 
(6) COMPOUNDS INLUDED IN Annex IV to Council Regulation (EEC) N° 2377/90 of 
26 June 1990. 
 
GROUP B – Veterinary drugs and contaminants 
 
(1) Antibacterial substances, including sulphonalides, quinolones 
(2) Other veterinary drugs 
(a) Anthelmintics 
(b) Anticoccidials, including nitroimidazoles 
(c) Carbamates and pyrethroids 
(d) Sedatives 
(e) Non-steroid anti-inflammatory drugs (NSAIDs) 
(f) Other pharmacologically active substances 
(3) Other substances and environmental contaminants 
(a) Organochlorine compounds including PCBs 
(b) Organophosphorus compounds 
(c) Chemical elements 
(d) Mycotoxins 
(e) Dyes 
(f) Others 
 
PERFORMANCE CRITERIA 
 
It is quite obvious that a sound analytical methodology is required for the monitoring of the 
compliance with the directive 96/22/EC. 
Criteria for identification and confirmation, both for qualitative and quantitative methods by 
means of various analytical principles were set out in Decision 93/256/EEC (3) and 93/257/EEC 
(4). These criteria have now been re-examined in other to take account of developments in 
scientific and technical knowledge. A provisional document has been circulating for a couple of 
years and has been used semi-officially as the basis of future criteria in many publications. It 
was referred to as the SANCO document 1085/2000. By Commission Decision 2002/657/EC of 
12 August 2002, this document, after long political discussions, has finally been adopted. The 
Decision shall apply from 1 September 2002 (5). Nevertheless transitional provisions have been 
included. Methods for the analysis of official satisfy the criteria set out in Decisions 
93/256/EEC and 93/257/EEC may be used for up to two years after this Decision enters into 
force. Methods currently applied for substances listed in group B of that Annex shall comply 
with this Decision at the latest five years after the date of application of this Decision. 
The Council Regulation 2377/90 fixes maximum residue limits or MRL’S (6). These are the 
maximum concentrations of residue resulting form the use of a veterinary medicinal product 
(expressed in mg/kg or µg/kg on a fresh weight basis which may be accepted by the Community 
to be legally permitted or reorganized as acceptable in or on a food. It is based on the tyre and 
amount of residue considered to be without any toxicological hazard, for human health as 
expressed by the acceptable daily intake (ADI), or on the basis of a temporary ADI that utilizes 
and additional safety factor. 
The Regulation has for annexes, each containing a list of substances. Annex I is the list of 
pharmacologically active substances for which maximum residue levels have been fixed. It 
contains anti-infections agents, anti-parasitic agents, agents acting on the central nervous 
system, anti-inflammatory agents, corticoids, agents acting on the reproductive system. Annex 
II is the list of substances not subject to maximum residue levels consequently, these are of no 
importance for this publication. They comprise inorganic chemical, organic compounds, 
substances generally recognised as safe, substances used in homeopathie veterinary medicinal 
products, substances used as food additives in foodstuffs for human consumption (substances 
with an E number) and substances of vegetable origin. 
Annex III is the list of pharmacologically active substances used in veterinary medicinal 
products for which provisional maximum residue limits have been fixed. They include anti-
infections agents, antiparasitic agents, anti-inflammatory agents and agent acting on the 
reproductive system. Finally the annex IV contains the list of pharmacologically active 
substances for which no maximum levels can be fixed. This means in other terms that no 
residues of these substances may be detectable. The forbidden substances are updated  to 
25.11.2002. Aristolochia spp. and preparations thereof, Chloramphenicol, Chloroform, 
Chlorpromazine, Colchicine, Dapsone, Dimetridazole, Metronidazole, Nitrofurans (including 
furazolidone), Ronidazole.  
 
GENERAL ANALYTICAL APPROACH 
 
In the preambles of the Commission Decision 2002/657/EC it is stated that it is necessary to 
ensure the quality and comparability of the analytical results generated by laboratories approved 
for official residue controls. This should be achieved by using quality assurance systems and 
specifically by applying of methods validated according to common procedures and 
performance criteria and by ensuring tracebility to common standards or standards commonly 
agreed upon. 
Official control laboratories must be accredited according to ISO 17025 from January 2002 
onwards. Participation in an internationally recognised external quality control assessment and 
accreditation scheme is required for approved laboratories. Moreover, approved laboratories 
must prove their competence by regular and successful participation in adequate proficiency 
testing schemes, recognised or organised by the national or Community reference laboratories. 
As a result of advances in analytical chemistry since the adoption of Directive 96/23/EC  the 
concepts of routine methods and reference methods have been superseded by criteria approach, 
in which performance criteria and procedures for the validation of screening and confirmatory 
methods are established. 
In order to ensure harmonised implementation of Directive 96/23/EC it is necessary to provide 
for the progressive establishment of minimum required performance limits (MRPL) of 
analytical methods for substances for which no permitted limit has been established and in 
particular for those substances whose use it not authorised, or is specifically prohibited in the 
Community. Therefore the Commission Decisions 93/256/EEC and 93/257/EEC have been 
repealed with the Decision 2002/657/EC. The latter introduces new approaches with regard to 
the interpretation of results. Terms like positive or negative are being replaced by non-compliant 
and compliant. The result of an analysis shall be considered non-compliant if the decision limit 
of the confirmatory method for the analyte is exceeded. If a permitted limit has been established 
for a substance, the decision limit is the concentration above which it can be decided with a 
statistical certainty of 1-á that the permitted limit has been duly exceeded. If no permitted limit 
has been established for a substance, the decision limit is the lowest concentration at which a 
method can discriminate with a statistical certainty of 1-á that the particular analyte is present. 
For substances listed in Group A (Table 1) of Annex I to Directive 96/23/EC, the á error shall 
be 1% or lower. For all other substances, the á error shall be 5% or lower. 
The annex of Commission Decision contains a list of 46 definitions, all related to performance 
criteria, other requirements and procedures for analytical methods. The most relevant ones with 
regard to the theme of this lecture are the following : 
Alpha (á) error means the probability that the tested sample is compliant, even though a non-
compliant measurement has been obtained (false non-compliant decision). 
Beta (ß) error means the probability that the tested sample is truly non-compliant, even though 
a compliant measurement has been obtained (false compliant decision). 
Confirmatory method means methods that provide full or complementary information enabling 
the substance to be unequivocally identified and if necessary quantified at the level of interest. 
Decision limit (CCá) means the limit at and above which it can be concluded with an error 
probability of á that a sample is non-compliant. 
Detection capability (CCß) means the smallest content of the substance that may be detected, 
identified and/or quantified in a sample with an error probability of ß. In the case of substances 
for which no permitted limit has been established, the detection capability is the lowest 
concentration at which a method is able to detect truly contaminated samples with a statistical 
certainty of 1 – ß. In the case of substances with an established permitted limit, this means that 
the detection capability is the concentration at which the method is able to detect permitted limit 
concentrations with a statistical certainty of 1 – ß. 
Minimum required performance limit (MRPL) means minimum content of an analyte in a 
sample, which at least has to be detected and confirmed. It is intended to harmonise the 
analytical performance of methods for substances for which no permitted limit has been 
established. 
Screening method means methods that are used to detect the presence of a substance or class of 
substances at the level of interest. These methods have the capability for a high sample 
throughput and are used to sift large numbers of samples for potential non-compliant results. 
They are specifically designed to avoid false compliant results. 
Only those analytical techniques, for which it can be demonstrated in a documented traceable 
manner that they are validated and have a false compliant rate < 5% (ß-error) at the level of 
interest shall be used for screening purposes. In the case of a suspected non-compliant result, 
this result shall be confirmed by a confirmatory method. 
Confirmatory methods for organic residues or contaminants shall provide information on the 
chemical structure of the analyte. Consequently methods based only on chromatographic 
analysis without the use of spectrometric techniques are not suitable on their own for use as 
confirmatory methods. However if a single technique lacks sufficient specificity, the desired 
specificity shall be achieved by analytical procedures consisting of suitable combinations of 
clean-up, chromatographic separation(s) and spectrometric detection.   
An extensive discussion on the performance of analytical methods and the interpretation of the 
results, by the same others of this paper will be published in the near future (7). 
 
SAMPLE PREPARATION  
Basically sample preparation includes, except for liquid samples, an homogenization with water 
or an appropriate aqueous solution, followed by a centrifugation step. For concentrations below 
the µg/kg or ppb range, concentration and thus removal of potentially interfering substances is 
required (clean up). 
An alternative to homogenization is the enzymatic digestion of the tissue by means of 
proteolytic enzymes such as subtilisin. 
Homogenates as well as digestates subsequently need to extracted with an organic solvent. 
Deconjugation of sulphates and glucuronides is easily performed by means of Helix pomatia 
juice or similar preparation. Solid phase extraction (SPE) on commercially available disposable 
column has become the most common technique for selective sample clean up. As some cases 
semi-preparative HPLC automated fraction collection is performed. Matrix solid-phase 
dispersion (MSPD), as proposed initially by Barker in 1989 (8) has lost some of its importance 
in the last decade, mainly because of the lost of the required adsorptive material. 
On the other hand there is an increasing popusanty of Immunoaffinity chromatography. 
A more recent technique to gain selectivity, and thus a more efficient clean-up, is to use 
molecularly imprinted polymers (MIPs) as sorbent material in solid phase extraction. MIPs are 
artificial recognition systems normally based on non-covalent forces, thus trying to mimic 
nature (9). A template, the analyte itself or a structurally related analogue is first allowed to 
form bonds with functional monomers in a solvent. Subsequently the monomers are crosslinked 
and the template extracted from the polymer, leaving specific cavities in regard to shape and 
functionality. These cavities can rebind the analyte of structurally related compounds and thus a 
selective clean-up can be obtained. When compared to antibodies, MIPs offer several 
advantages in that they are stable at relatively high temperatures, in organic solvents and over a 
wide pH range. Moreover MIPs often can be developed within a couple of weeks, in contrast to 
the long development times normally required for antibody production in animals. 
 
SCREENING METHODS  
 
The development of radioimmunoassay (RIA) by Yalow and Berson in 1960 (10) as an 
extremely sensitive technique for the detection and quantification of very small quantities of 
endogenous compounds in biological matrices caused a real revolution in clinical chemistry. 
Since then, the analytical principle made its way into other disciplines, including veterinary 
drug residue analysis, where it is still of crucial importance for screening large sample numbers. 
The term enzyme immunoassay (EIA) encompasses all immunoassays in which either the 
antigen or the antibody is enzyme-labeled. In a more restricted definition it is analogous to RIA. 
Like RIA it requires the separation of free and bound phases, and it is therefore referred to as a 
heterogenous immunoassay. The homogenous EIA or enzyme-mediated immunoassay 
technique (EMIT) does not depend on free and bound label separation to enable the degree of 
competition. It relies on the use of enzyme-hapten conjugates in which enzyme activity is 
altered when it binds with the antibody. These tests can provide very rapid results (a few 
minutes) but something suffer from a lack of sensitivity. Heterogenous immunoassays are 100-
1000 times more sensitive. 
Enzyme-linked immunosorbent assays (ELISA) encompass all solid-phase immunoassays using 
enzyme-labeled reagents. Three versions are of common use in food analysis : direct 
competitive ELISA, indirect ELISA, and double -antibody or sandwich ELISA. 
Several fluorescent molecules have been used for labeling both antigens and antibodies. The 
fluorescent signal of the assay endpoint can be measured quickly and simply by means of 
readily available and relatively inexpensive equipment. Fluorescein has been the most 
commonly used label. Others are rhodamines, umbelliferones, and rare earth metal chelates. The 
main disadvantages that have limited the development of fluorescence immunoassay (FIA) are 
light-scattering effects, inner filter effects, quenching, and, especially endogenous fluorophores 
such as bilirubin in the samples. 
Luminescent labels were first introduced in clinical chemistry. Luminescence is divided into 
bioluminescence and chemiluminescence. Bioluminescence occurs in many living organisms, 
the oxidation step leading to high emission being catalyzed by a group of enzymes, the 
luciferases. The substrates for luciferase are kwown as luciferin. Both firefly and bacterial 
luciferase have been used to label antigens. Also the cofactors such as ATP and NAD that are 
necessary for the luciferase reaction can be used for labeling purposes. 
Chemiluminescence is produced in certain chemical reactions in which the energy released 
during the reaction is sufficient to produce light quanta. Most chemiluminescent reactions are 
oxidation reactions. Luminescent compounds that have been used as labels include luminol, 
isoluminol, ABEI [N-(4-aminobutyl)-N-ethyl isoluminol], AHEI [N-(6-aminohesxyl)-N-ethyl 
isoluminol] and ABEI-H [N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide]. The light is 
produced by oxidation by hydrogen peroxides or other peroxides. In most cases the reaction is 
catalyzed by metal-containing complexes or enzymes containing heme such as microperoxidase. 
To a lesser extent, aryl acridinium esters have also been used for labeling purposes. 
Luminescent labels can be easily incorporated into established RIA techniques, yielding 
fluorescence immunoassays (FIAs) with similar or improved sensitivity and short measurement 
times. The feasability of homogenous or nonseparation assays has been demonstrated by Kohen 
et al. (11,12). 
A rather novel technique in food analysis is the use of biosensors. The optical surface plasmon 
resonance (SPR) biosensor has in recent years to be proven to be a useful technique for simple, 
rapid and nonlabeled determination of various biochemical analytes. Proteins, complex 
conjugates, toxins, allergens, drugs and pesticides can be determined using natural antibodies or 
synthetic receptors. When small molecules are to be measured an inhibition assay format is 
used, since low molecula r weight substances are difficult to measure directly due to mass 
sensitivity limitations of current instruments. In the inhibition assay format a fixed 
concentration of antibody is added to the sample and if analyte is present binding will occur and 
some of the antibody sites will be blocked. An interchangeable and reusable chip (gold coated) 
with the analyte covalently immobilised on the sensor surface is used to determine free antibody 
concentration in solutions versus a calibration curve. Analyte concentration is consequently 
measured in terms of inhibition of antibody binding to the surface. 
 
CONFIRMATORY METHODS 
 
Whereas immunochemical methods play a predominant role in screening for the presence of 
forbidden growth promoters in food products, the various existing chromatographic techniques 
are the most intensively used methods for confirmatory purposes. The use of thin-layer 
chromatography is very limited nowadays due to the availability of mass spectrometry 
techniques in the routine laboratories. The last few years, liquid chromatography coupled to 
mass spectrometry has become the method of choice for the confirmation and quantification of 
residues of growth promoters, especially for corticosteroids. Non-volatile and thermolabile 
compounds can be analysed directly without derivatization. 
Specificities in the analysis of veterinary drug residues, usually occurring at sub-µg/kg levels, 
can be achieved by either a lengthy sample preparation and cleanup to separate the analyte from 
potential interferences or by using a less selective workup but a more specific detector. As a 
direct consequence of the latter approach, increased MS specificity is pursued by the use of 
tandem mass spectrometry, which becomes more and more available to routine laboratories. 
Because there are no maximum residue limits for most growth promoters, emphasis is laid on 
specificity rather then on accuracy and precision. The use of isotope-labeled internal standards 
is limited because of the unavailability of most deuterated homologs of the analyte. 
The target matrices for the detection of residues of growth promoters in edible products of 
animal origin are mainly muscle tissue, liver, kidney and fat. Non-edible matrices (urine, faeces, 
retina, hair, …) are also frequently used to perform the control on the abuse of growth 
promoters. 
All these materials have a highly complex composition that is subject to variations, depending 
on animal species, tissue type, and the nutritional regime of the animal. In most cases the parent 
compound – the molecule that has been administered – is considered the target molecule and 
therefore traced. Little is known about the chemical form in which residues are deposited in the 
animal tissues. Well-known exceptions are 19-nortestosterone, stanozolol and 
chlorotestosterone acetate. 
 
SUMMARY 
 
A review of the most recent methodology is about to be published by the same authors of this 
contribution (7). 
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